William Blair initiated coverage on Zevra Therapeutics
$ZVRA
Biotechnology: Pharmaceutical Preparations
Health Care
William Blair initiated coverage of Zevra Therapeutics with a rating of Outperform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/7/2024 | $20.00 | Buy | Guggenheim |
| 9/24/2024 | $17.00 | Mkt Outperform | JMP Securities |
| 9/24/2024 | $18.00 → $25.00 | Buy | Maxim Group |
| 4/2/2024 | $12.00 → $18.00 | Buy | Maxim Group |
| 3/12/2024 | Outperform | William Blair | |
| 3/17/2023 | $12.00 | Buy | Maxim Group |
10-Q - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)
8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)
8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)
Guggenheim initiated coverage of Zevra Therapeutics with a rating of Buy and set a new price target of $20.00
JMP Securities initiated coverage of Zevra Therapeutics with a rating of Mkt Outperform and set a new price target of $17.00
Maxim Group reiterated coverage of Zevra Therapeutics with a rating of Buy and set a new price target of $25.00 from $18.00 previously
SC 13G - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)
SC 13G/A - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)
SC 13G/A - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)
CELEBRATION, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced it will report third quarter financial results and provide a corporate update on Tuesday, Nov. 12, 2024. The Company will issue a news release after the market closes and host a conference call/audio webcast at 4:30 p.m. ET that day. The corporate update will include recent progress with the commercial launches of MIPLYFFA™ and OLPRUVA® as well as the Company's clinical stage programs. A link to the audio webcast will be accessible on the "Events & Presentations"
MIPLYFFA is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), an ultra-rare and progressive neurodegenerative disease MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of NPC in adults and pediatric patients 2 years of age and older Zevra receives rare pediatric disease priority review voucher in conjunction with approval Company launches AmplifyAssist™ patient support program Conference call and webcast set for 8:00 a.m. EDT on Monday, Sept. 23, 2024 CELEBRATION, Fla., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage rare disease therap
CELEBRATION, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced that it will host a conference call and audio webcast on Tuesday, August 13, 2024, at 4:30 p.m. ET, to review its corporate and financial results for the second quarter of 2024. The link to the audio webcast will be accessible via the Investor Relations section of the Company's website, https://investors.zevra.com/. To join the meeting by conference call, use the dial-in information below. (800) 225-9448 (U.S.)+1 (203) 518- 9708 (International)Conference ID: ZVRAQ224 An archive of the webcast will be available for 90 da
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume BSX PUT SWEEP BEARISH 08/16/24 $75.00 $68.9K 5.5K 2.1K MRNA CALL SWEEP NEUTRAL 11/15/24 $170.00 $121.
Although U.S. stocks closed mixed on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company’s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga’s insider transactions platform. Zevra Therapeutics The Trade: Zevra Therapeutics, Inc. (NASDAQ:ZVRA) CFO & Treasurer R. Laduane Clifton acquired a total o
Although U.S. stocks closed higher on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company’s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga’s insider transactions platform. Barnes & Noble Education The Trade: Barnes & Noble Education, Inc. (NYSE:BNED) Director Eric Singer acquired a total of 18,
Rahsaan W. Thompson appointed as Chief Legal Officer, Secretary and Compliance Officer Alison Peters appointed as Chief People Officer CELEBRATION, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the appointments of Rahsaan W. Thompson as Chief Legal Officer, Secretary and Compliance Officer, and Alison Peters as Chief People Officer. Both Mr. Thompson and Ms. Peters bring deep expertise in building high-performing teams which will be essential to deliver success through the Company's next phase of growth. "We are thrilled to welcome both Rahsaan and Alison to the Zevra team as w
CELEBRATION, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, Zevra's President and Chief Executive Officer, has issued a Letter to Stockholders providing a review of key accomplishments and outlook for 2024. Dear Stockholders, It is hard for me to believe that April 2024 marks six months since the start of my tenure as Zevra's President and Chief Executive Officer in October 2023. From that time, and even prior to my official start date, I began a listening tour, seeking feedback from many of Zevra's stakeholders – stockholders, investors, employees, patie
CELEBRATION, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the appointment of Alvin Shih, MD, MBA, to the Company's Board of Directors (Board) effective as of January 20, 2024. Dr. Shih has extensive experience in biotechnology leadership and rare disease therapeutics development and currently serves as President and CEO of Catamaran Bio, a biotechnology company developing cell therapies for multiple oncologic indications. "We are honored to welcome Dr. Shih to our Board as we advance our therapeutic portfolio of product candidates in multiple rare disease indications," said Tamar
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)
MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, is available at Zevra's specialty pharmacy for dispense AmplifyAssist™, Zevra's comprehensive patient support program, in place to address access barriers CELEBRATION, Fla., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage rare disease therapeutics company, today announced that MIPLYFFA™ (MY-PLY-FAH) (arimoclomol), the first treatment approved by the U.S. Food and Drug Administration (FDA) for the treatment of Nieman Pick disease type C (NPC), is now commercially available for dispense. MIPLYFFA is indicated for use in combination with miglus
FDA approval of MIPLYFFA™ and product launch cap third quarter filled with multiple commercial and clinical development milestones Zevra received rare pediatric disease Priority Review Voucher Company ends quarter with cash, cash equivalents and investments of $95.5 million Company to host conference call and webcast today, Nov. 12, 2024, 4:30 p.m. ET CELEBRATION, Fla., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today reported its financial results for the t
Data show that the NPCCSS swallow score reflects the patient's level of dysfunction Study indicates that a change in score reflects actual improvement or worsening in a patient's swallowing function CELEBRATION, Fla., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced that Elizabeth Berry-Kravis, M.D., Ph.D., Professor of Pediatrics, Neurological Sciences, and Biochemistry at Rush University Medical Center in Chicago, is presenting data demonstrating the relevance of the swallow domain as part of the Niemann-Pick disease T